Why carry out this study?
|
The objective of our 24-week multicenter, randomized, double-blind, placebo-controlled study was to determine the safety and efficacy of repository corticotropin injection (RCI; Acthar® Gel) in patients with persistency active systemic lupus erythematosus (SLE). |
The primary results from this study showed that RCI was associated with improvements in the 28 Swollen and Tender Joint Count and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-Activity scores. Post hoc analyses found a greater proportion of British Isles Lupus Assessment Group-based Combined Lupus Assessment (BICLA) responders for RCI than for placebo and a greater SLE Responder Index-4 response in RCI-treated patients with baseline SLE Disease Activity Index-2000 (SLEDAI-2K) ≥ 10, CLASI-Activity ≥ 11, and British Isles Lupus Assessment Group (BILAG)-2004 ≥ 20 than in patients with lower disease activity. |
Here we report the patient-reported outcome results from this study and further characterize the effects of RCI on quality of life (QoL) and work productivity as they relate to baseline disease activity. |
What was learned from this study?
|
Treatment with RCI was associated with greater improvements in the LupusQoL pain, planning, and fatigue domains compared to placebo treatment in patients with baseline SLEDAI-2K ≥ 10, CLASI-Activity ≥ 11, and BILAG-2004 ≥ 20 and/or in BICLA responders. Treatment with RCI was also associated with greater improvements in the Work Productivity and Activity Impairment (WPAI)-Lupus absenteeism (percentage work time missed) and presenteeism (percentage impairment while working) domains compared to placebo treatment in patients with baseline CLASI-Activity < 11 and in BICLA responders, respectively. |
The improvements in QoL and work productivity observed in this study further support the efficacy of RCI for the treatment of persistently active SLE despite use of moderate-dose glucocorticoids. |
Open Access 01.03.2021 | Original Research
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Erschienen in: Rheumatology and Therapy | Ausgabe 1/2021